RXRX RECURSION PHARMACEUTICALS INC

Altitude Lab Startups Raise Over $120M in Capital

Altitude Lab Startups Raise Over $120M in Capital

Launches Fellowship Grant Opportunity for Early Career Entrepreneurs

SALT LAKE CITY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- today announced that its incubating startups raised over $120M in early-stage funding since commencing operations in 2020. Altitude Lab was founded by Recursion to support burgeoning startups and underrepresented entrepreneurs in Utah with fully equipped laboratories, a network of investors, business operations education, and a community of founders. To further advance this mission, the incubator also announced today the launch of the , a funding opportunity to enable early-career scientists to launch their own startups.

“Despite an extremely challenging funding climate, our 18 startups have continued to be creative and build impressive companies and technologies. Investors are increasingly watching Utah as a growing biotechnology hub. In 2021 we announced our , which targeted $50M in funding for our startups. It's a really proud moment to more than double that goal today,” said Chandana Haque, executive director of Altitude Lab.

While this funding milestone speaks to the strong growth of Utah’s biotech ecosystem, enabling young and underrepresented entrepreneurs continues to be a challenge.  Many promising technologies are developed in academic research labs where students are inventing medical breakthroughs but are unaware of how to bring their innovations to patients. Universities have improved the racial and gender diversity in their programs but these students still lack the resources and mentorship to inspire company building. In partnership with Chris and Summer Gibson, Altitude Lab has launched the to bridge these gaps.

“Unlike other STEM fields, life science has an extremely diverse funnel of talent. If we want this talent to stay in Utah, take the entrepreneurial leap, and build the next era of medicine, we need to arm them with the resources, mentors, and funding to do it. That’s why my wife, Summer Gibson, MD, and I are thrilled to support this fellowship,” said Chris Gibson, PhD, Co-Founder and CEO of Recursion. “Recursion founded Altitude Lab to provide the infrastructure Utah needed to excel in biotechnology. This fellowship allows us to support entrepreneurs in a much more personal way. Summer and I both did our graduate training in Utah and we are very proud to help more ambitious students translate their work to patients and shape Utah’s biotech industry.”

The Founder Fellowship offers up to $100,000 in funding, scientific tools and laboratories, and monthly mentoring with Chris Gibson to two fellows each year. Fellows must be within 12 months of finishing their training to qualify for the fellowship. Applications are open now and close April 12, 2024. Learn more about Altitude Lab and apply for residency and the Founder Fellowship at

About Altitude Lab

is building a new, representative generation of founders to seed the next cycle of health care innovation in Utah's . Currently located in Gateway’s BioHive Hub in Salt Lake City, Altitude Lab is an incubator focused on early stage life science and health care companies. The initiative is part of a and from to foster socially-responsible entrepreneurship, job creation, and economic productivity. The Recursion Foundation, under which Altitude Lab operates, is a 501(c)(3) nonprofit organization.

Learn more at or connect on .

About Recursion

Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of , the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal and the San Francisco Bay Area. Learn more at , or connect on and .



Media Contact
 

Investor Contact
 
EN
24/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RECURSION PHARMACEUTICALS INC

 PRESS RELEASE

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonst...

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, with a 53% median reduction observed from baselineNatural history analysis showed that 87% of unt...

 PRESS RELEASE

Recursion Announces Webinar For Upcoming Clinical Data Readout on the ...

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in FAP at an upcoming company webinar. The webinar will be held on December 8, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT, and will be streamed live on Recurs...

 PRESS RELEASE

Recursion Reports Third Quarter 2025 Financial Results and Provides Bu...

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of neurological diseasesWith this achievement, Recursion will have reached over $500 million in milestone and upfront payments across all its partnerships and collaborationsApproximately $785 million of cash and cash equivalents (unaudited) as of October 9, 2025- runway through the end of 2027, without additional financing...

 PRESS RELEASE

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board of Directors has unanimously approved a leadership transition plan to become effective January 1, 2026: Najat Khan, Ph.D., currently Chief R&D and Commercial Officer and a Board Member...

 PRESS RELEASE

Recursion to Participate in Upcoming Investor Conferences

Recursion to Participate in Upcoming Investor Conferences Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference — Tuesday, November 11, 2025 Jefferies Global Healthcare Conference London — Tuesday, November 18, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at .About RecursionRecursion (NASDA...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch